Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 4,053 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 4,053 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $807,519.72. Following the completion of the sale, the chief financial officer directly owned 119,216 shares of the company’s stock, valued at approximately $23,752,595.84. This trade represents a 3.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jack Anders also recently made the following trade(s):

• On Wednesday, June 24th, Jack Anders sold 20,000 shares of Revolution Medicines stock. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00.

Revolution Medicines Stock Performance

Shares of RVMD opened at $190.95 on Friday. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines, Inc. has a 52-week low of $42.18 and a 52-week high of $224.31. The company has a 50-day simple moving average of $199.57 and a 200-day simple moving average of $159.57. The company has a market capitalization of $40.93 billion, a PE ratio of -21.65 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the previous year, the firm earned ($1.31) EPS. Equities research analysts predict that Revolution Medicines, Inc. will post -8.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on RVMD. Needham & Company LLC raised their price objective on Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Mizuho boosted their target price on Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Wedbush upped their target price on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Friday, July 17th. Finally, TD Cowen raised Revolution Medicines to a “strong-buy” rating in a research note on Monday, August 24th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Revolution Medicines has an average rating of “Moderate Buy” and a consensus target price of $226.17.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Revolution Medicines recently received regulatory approval for a new medicine, validating its approach to treating certain cancers. The treatment could potentially become the most-prescribed therapy in its indication, improving the company’s long-term commercial outlook. Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
• Neutral Sentiment: A comparison article weighing Axsome Therapeutics against Revolution Medicines highlights RVMD as a healthcare investment candidate, but does not provide a clearly new company-specific catalyst. Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
• Negative Sentiment: Five company insiders, including the CFO and COO, collectively sold approximately $5.8 million of RVMD shares at $199.24 apiece. The filings state that the transactions were made to cover tax withholding obligations tied to vested equity awards, rather than for discretionary reasons. Nevertheless, the cluster of sales can create short-term supply and sentiment pressure. The insiders continued to hold substantial positions after the transactions. Revolution Medicines insider transaction filing

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RVMD. Sequoia Financial Advisors LLC purchased a new stake in Revolution Medicines in the 2nd quarter worth approximately $626,000. MCF Advisors LLC purchased a new position in shares of Revolution Medicines during the 2nd quarter worth $78,000. National Pension Service purchased a new position in shares of Revolution Medicines during the 2nd quarter worth $51,241,000. Engineers Gate Manager LP boosted its holdings in shares of Revolution Medicines by 144.0% during the second quarter. Engineers Gate Manager LP now owns 7,380 shares of the company’s stock worth $1,382,000 after purchasing an additional 4,356 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Revolution Medicines in the second quarter valued at $278,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.